Mithra trims conversion price for convertible bonds due 2025

By Wendy Van Sickle

Columbus, Ohio, Sept. 12 – Mithra Pharmaceuticals SA adjusted the conversion price on its €125 million senior convertible bonds due 2025 (ISIN: BE6325746855), according to a Tuesday press release.

The conversion price was decreased to €23.237 from €23.8262, effective as of Aug. 28.

The adjustment is a result of the company’s issuance of 10 million new ordinary shares at a price of €2.00 each, as part of a private placement.

Mithra is a Liege, Belgium-based biopharmaceutical company focused on women’s health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.